Loading…
BSP Pharmaceuticals
End-to-end pharmaceutical services for oncological and non-cytotoxic innovative drugs
About
BSP Pharmaceuticals is an Italian CDMO whose campus at Latina Scalo hosts two segregated facilities serving clients from pre-clinical GLP development through cGMP manufacturing for clinical and commercial supply of cytotoxic and high-potent oncology drugs and non-cytotoxic compounds (stated up to OEB 6), plus innovative compounds for immunotherapy. The facilities are designed to handle small and large molecules including ADCs (both conjugation and fill-finish), peptides, proteins, oligonucleotides and nanomedicines. Services include formulation and process development and optimisation with scale-up and scale-down studies, and QC laboratories covering analytical testing. The campus was created on the site of a former Tetra Pak facility with an initial investment of EUR 80 million.
Deterministic scores · rules-based, not AIiHow these scores are obtained: each one is computed from this profile's listed attributes — capability checkboxes, certifications, capacity figures and coverage — by a fixed formula, recomputed on every page load. Deterministic and rules-based means the score comes from a fixed, transparent formula over listed attributes — the same inputs always produce the same score. It is not AI: there is no model, no learning, and no hidden weighting. Whether a score is relevant to you depends on your specific project: a capability that raises the number may not matter for your work, and a niche strength your project needs may barely move it. Capability scores are a directional starting point, not a verdict. A lower score does not disqualify a company or consultant, and no decision should rest on the score alone — always contact the company directly to confirm the specifics for your project.
Manufacturing iCounts how many of the 22 core manufacturing capabilities this profile lists (7 drug-substance, 6 drug-product, 5 advanced-therapy, 4 specialized) - each adds 3.6 points, capped at 78 - plus 2.4 points per therapeutic area covered, capped at 22. Levels: 80+ Full-spectrum CDMO | 60-79 Broad capability | 40-59 Established | below 40 Focused. Whether this dimension matters for you depends on your specific project.
26Focused
Advanced therapy iCounts the 5 advanced-therapy capabilities (cell therapy, gene therapy, viral vectors, CAR-T, exosomes) at 11 points each, capped at 50, then adds bonuses for related depth: biologics drug substance 14, mRNA 12, viral vectors 10, CAR-T 8, plasmid DNA 6. Levels: 80+ ATMP leader | 60-79 Advanced | 40-59 Emerging | below 40 Limited. Whether this dimension matters for you depends on your specific project.
0Limited
Fill-finish iCounts the 6 fill-finish capabilities (vial, syringe, cartridge, blow-fill-seal, isolator, RABS) at 8 points each, capped at 42, plus 16 for sterile injectables, 12 for isolator filling, 8 for RABS. Suite count adds up to 22 more (22 at 20+ suites, 16 at 10+, 10 at 5+, 5 for any). Levels: 80+ High-capacity sterile | 60-79 Strong | 40-59 Capable | below 40 Developing. Whether this dimension matters for you depends on your specific project.
16Developing
Quality iBlends GMP certification (16), Annex 1 compliance (14) and a data-integrity program (10) with reported metrics: inspection pass rate up to 24, quality score up to 18, plus bonuses for low CAPA counts (up to 8) and few audit findings last year (up to 10 for zero). Shows Not reported (score 0) when no GMP flag, pass rate, quality score or data-integrity program is on file. Levels: 80+ Exceptional | 60-79 Strong | 40-59 Solid | below 40 Developing. Whether this dimension matters for you depends on your specific project.
0Not reported
Regulatory iCounts entries in three profile lists: regulatory history (6 points each, capped at 46), inspection authorities (7 points each, capped at 30) and geographic coverage (6 points each, capped at 24). More filings, more agencies and wider geography all raise the score. Levels: 80+ Global reach | 60-79 Multi-region | 40-59 Regional | below 40 Limited. Whether this dimension matters for you depends on your specific project.
0Limited
Capacity iTiers four scale metrics: facilities (up to 28 points at 30+), manufacturing suites (up to 24 at 40+), annual unit capacity (up to 26 at 1,000,000+) and employee count (up to 22 at 10,000+). Each metric earns partial points at lower tiers, so any reported scale contributes. Levels: 80+ Global scale | 60-79 Large | 40-59 Mid-size | below 40 Boutique. Whether this dimension matters for you depends on your specific project.
9Boutique
Capabilities
Sterile fill-finishPeptidesHPAPIOral solidsProcess devClinical mfgCommercial mfg
Technology platforms
ADC conjugation and fill-finish; high-containment handling of cytotoxics and high-potent compounds (company states preparation of anticancer products with an OEL lower than 10 ng/m3and non-cytotoxics up to OEB 6); liposomal and lipid-based formulations; micro- and nano-emulsions; peptidesproteinsoligonucleotides and nanomedicines
Therapeutic areas
Oncologyimmunotherapy
Live record · illustrative seed data · scores deterministic, rules-based — not AI.